Notably, semaglutide, a GLP-1 receptor agonist used to treat T2D, has been associated with a reduced risk of a first-time Alzheimer’s diagnosis in a large cohort of T2D patients 94. This evidence concerns the gene GLP1R and type 2 diabetes mellitus.